Expert Practice
Expert Practice
Expert Practice

Expert Practice in Pancreatic Cancer

Maximizing Patient Care With Innovation and Collaboration

Not a member of My prIME? Join now for instant access.

Meeting Overview

Apply now to engage with experts in the field of pancreatic cancer (PCA) by joining this highly interactive 1.5-day live meeting. Our multidisciplinary experts will provide a comprehensive update on the management of PCA, focusing on recent developments for patients with resectable, unresectable, and metastatic PCA as well as supportive care and adverse event management. This exciting meeting will use the following strategies:

  • Didactic presentations
  • Case-based presentations and clinical management discussions
  • Quiz questions
  • Q & A sessions

Date and Location

Friday and Saturday
28 – 29 September 2018

Room: Paris
Renaissance Wien
Linke Wienzeile/Ullmannstrasse 71
Vienna, Austria

Travel Grant Information

To apply for a travel grant, click on the Apply Now button.



28 – 29 September 2018



Vienna, Austria



Friday, 28 SeptemberDay 1

18.30 Buffet dinner
19.00 Welcome, introduction, and demographics
Philip Agop Philip, MD, PhD, FRCP, Thomas Seufferlein, MD, PhD, and Eric Van Cutsem, MD, PhD
19.10 Brain teasers
19.20 PCA management: Why is it so challenging?
Gerald Prager, MD
19.45 Audience questions and faculty panel commentary
19.55 Clinical case: The value of a multidisciplinary treatment approach in PCA
Thomas Seufferlein, MD, PhD
20.35 Audience questions and faculty panel commentary
20.45 Concluding remarks

Saturday, 29 SeptemberDay 2

07.30 Breakfast
08.30 Introduction and objectives of Day 2

Session I: Improving Outcomes in Patients With Resectable/Borderline Resectable PCA
Moderator: Eric Van Cutsem, MD, PhD

08.35 The role of radiologist in the multidisciplinary team: Defining resectability of PCA and beyond
Maria Antonietta Bali, MD, PhD
08.55 Contemporary management of resectable/borderline resectable PCA: Surgery or neoadjuvant therapy first?
Massimo Falconi, MD
09.20 Optimizing adjuvant therapy in PCA: Impact of new data
Eric Van Cutsem, MD, PhD
09.40 Ask the experts
10.00 Interactive clinical case and multidisciplinary tumor board discussion
Derek O’Reilly, PhD, FRCS
10.40 Coffee break

Session II: Multimodality Treatment of Locally Advanced PCA
Moderator: Thomas Seufferlein, MD, PhD

11.00 Systemic therapy for locally advanced PCA
Stefano Cascinu, MD, PhD
11.20 Update on locoregional treatment approaches for PCA
Thomas Brunner, MD
11.40 Ask the experts
11.50 Interactive clinical case and multidisciplinary tumor board discussion
Kalliopi Andrikou, MD
12.10 Supportive care measures throughout the patient’s cancer journey
Matti Aapro, MD
12.30 Ask the experts
12.40 Lunch

Session III:  Fine-Tuning Continuum of Care in Metastatic Pancreatic Cancer (mPCA) 
Moderator: Philip Agop Philip, MD, PhD, FRCP

13.40 Individualizing systemic therapy for mPCA across the disease continuum
Teresa Macarulla, MD, PhD
14.00 Ask the experts
14.10 Targeted therapy in mPCA: Are we moving forward?
Philip Agop Philip, MD, PhD, FRCP
14.35 Ask the experts
14.45 Interactive clinical cases and multidisciplinary tumor board discussion
Alicia Beutel, MD, and Helena Verdaguer, MD
15.25 Brain teasers revisited and faculty commentary
15.40 prIME Points™ and what to expect in PCA management in the coming years
Thomas Seufferlein, MD, PhD
15.55 Concluding remarks
16.00 Adjourn


  • Philip Agop Philip, MD, PhD, FRCPWayne State University and Karmanos Cancer Institute
    Detroit, Michigan, United States
  • Thomas Seufferlein, MD, PhD University of Ulm
    Ulm, Germany
  • Eric Van Cutsem, MD, PhDUniversity Hospitals Leuven
    Leuven, Belgium
  • Faculty

  • Matti Aapro, MDMultidisciplinary Oncology Institute
    Clinique de Genolier
    Genolier, Switzerland
  • Maria Antonietta Bali, MD, PhDInstitut Jules Bordet
    Free University of Brussels
    Brussels, Belgium
  • Thomas Brunner, MD, PhDUniversity Medical Center Freiburg
    Freiburg, Germany
  • Stefano Cascinu, MD, PhDUniversity of Modena and Reggio Emilia
    Modena, Italy
  • Massimo Falconi, MDUniversity Vita-Salute San Raffaele
    IRCCS San Raffaele Hospital
    Milan, Italy
  • Teresa Macarulla, MD, PhDVall d’Hebron University Hospital
    Barcelona, Spain
  • Gerald Prager, MDMedical University of Vienna
    Vienna, Austria

This educational activity is designed for European gastroenterologists, surgical, radiation, and medical oncologists, and other healthcare providers involved in the management of patients with PCA.

After successful completion of this educational activity, participants should be able to:

  • Identify risk factors for PCA and discuss reasons for poor outcomes and treatment resistance, including genetic diversity and role of PCA stroma
  • Recognize imaging criteria for resectability of PCA
  • Establish and implement multimodality treatment strategies for resectable, borderline resectable, and unresectable/locally advanced PCA, and discuss the importance of a multidisciplinary team approach
  • Select the most appropriate therapy for individual patients with metastatic pancreatic ductal adenocarcinoma in the first-line setting and beyond progression
  • Assess supportive care measures to ameliorate disease symptoms and treatment-related adverse events throughout the course of PCA management
  • Describe the potential role of genomic profiling and evaluate novel treatment approaches in PCA including targeted therapy for DNA repair defects, stromal targeting agents, agents targeting abnormal metabolism in PCA cells, and immunotherapeutic strategies

This educational activity is supported by grants from Celgene, ERYTECH, RAFAEL Pharmaceuticals, and Shire.

Continuing Education

Expert Practice in Pancreatic Cancer: Maximizing Patient Care With Innovation and Collaboration held in Vienna, Austria on 28–29 September 2018 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 7 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at

Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.

Good CME Practice


This activity is provided by prIME Oncology.


prIME Oncology complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements.


Disclosure of Relevant Financial Relationships

prIME Oncology assesses the relevant financial relationships of its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.